Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season

 

The purpose of the program is to continue the objectives of FOA IP10-007 to determine the effectiveness of empiric influenza antiviral therapy, in addition to empiric antibiotic therapy, for hospitalized CAP patients, and other patients with lower respiratory tract illness, during the periods when influenza viruses are circulating in the community. This program addresses the “Healthy People 2020” focus area(s) of Immunization and Infectious Diseases.

Deleted 09/09/2012 (Archived.) CDC-RFA-IP10-0070201SUPP12 Agency: Department of Health and Human Services
Office: CENTERS FOR DISEASE CONTROL Cooperative Agreement This award will be a continuation of funds intended only for grantee previously awarded under Funding Opportunity Announcement IP10-007, “Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season” (U18). A third year of patient enrollment is needed to obtain the sample size necessary to meet the objectives of this study. Despite good enrollment during the second year of the study, 2011-12, few influenza infections were identified. Flu activity was low through the U.S. Also, the number of LRTI hospitalizations was lower than previous years. An additional year would allow a larger sample size. Based on past performance, if current enrollment rates continue and there is 10-15% influenza, sample size will be met. 08/10/2012 This program does not have cost sharing or matching requirements. CDC
Procurement and Grants Office
TIMS
Phone 770-488-2700 PGOTIM@cdc.gov $846,000.00